

PHARMACY POLICY STATEMENT

Marketplace

DRUG NAME	Voxzogo (vosoritide)
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Voxzogo, initially approved by the FDA in 2021, is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. It acts as a positive regulator of endochondral bone growth as it promotes chondrocyte proliferation and differentiation. Achondroplasia is the most common form of skeletal dysplasia with an approximate prevalence of 1 in 20,000 live births. It is an autosomal dominant condition caused by a mutation in the FGFR3 gene which makes the protein that is involved in the development and maintenance of bone and brain tissue.

Voxzogo (vosoritide) will be considered for coverage when the following criteria are met:

Achondroplasia

For **initial** authorization:

1. Medication must be prescribed by or in consultation with a pediatric endocrinologist or geneticist; AND
2. Member has a diagnosis of achondroplasia with a FGFR3 gene mutation confirmed by genetic testing; AND
- 3.

For